These data combined with the fact that GALC-NSCs maintain neuronal stem cell markers (Figure S6A, related to Figure 4) highly suggest that GALC GE-NSCs retain their NSC biological characteristics and may be of therapeutic potential, which warrants future safety and efficacy investigation in relevant mouse models for the treatment of Krabbe disease and other demyelinating CNS disorders. The gene discussed is GALC; the disease is central nervous system disorder.